Skip to content

Avalo Therapeutics AVTX Convertible Preferred Stock Authorized Shares

Convertible Preferred Stock Authorized Shares at other companies

Immunovant, Inc. logo
Immunovant, Inc.IMVT
10M
Exelixis logo
ExelixisEXEL

Other financials

Income statement

See full
Revenue$59.0K-69.3%
Gross profit$963.0K+8,855%
Operating income-$20.9M-42.5%
Net income-$19.6M-49.3%
EPS (diluted)-$0.98+21.6%

Balance sheet

See full
Cash & equivalents$25.3M-79.8%
Total debt$328.0K-59.1%
Total equity$68.3M-44.3%
Total assets$99.9M-27.9%

Cash flow

See full
Operating cash flow-$17.7M-87.1%
CapEx-
Free cash flow-$15.0M-444%

Valuation

See full
Market cap$946.18M+1,783%
Enterprise value$921.19M-1,342%
P/S1,892.4×+1,852×

Profitability

See full
Gross margin182%+176pp
Operating margin-15,536.1%-17,275pp
Net margin-7,965.8%-10,750pp
FCF margin-11,123.8%-13,374pp

Returns & leverage

See full
Return on equity-88.8%
Debt / equity0.0×
Current ratio7.7×-14.9×

Where this comes from

Reported directly by Avalo Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avalo Therapeutics's convertible preferred stock authorized shares.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Avalo Therapeutics's convertible preferred stock authorized shares?
Avalo Therapeutics (AVTX) reported convertible preferred stock authorized shares of 5M in Q1 2026.
What does convertible preferred stock authorized shares mean?
Maximum number of convertible preferred shares the company is authorized to issue under its corporate charter.